Table 1.

Quantitation of KRAS^G12C mutant protein in human clinical FFPE tumor specimens.

Sample type	Sample Number	KRAS variant	Tumor Type	Tumor contenta	Total protein recovery (μg)	KRASG12C protein (fmol per 100 μg)	Range of engagement values within quantifiable limitsb
FFPE resected tumors	1	G12C	Adenocarcinoma	100%	180	48	10–90%
	2	G12C	Adenocarcinoma	100%	95	34c	15–85%
	3	G12C	Adenocarcinoma	90%	120	3	Outside quantifiable range
	4	G12C	Adenocarcinoma	25%	88	19c	26–74%
	5	G12C	Adenocarcinoma	65%	71	34c	15–85%
	6	G12C	Adenocarcinoma	60%	36	19c	26–74%
	7	G12C	Squamous cell carcinoma	60%	160	11	45–55%
	8	G12C	Squamous cell carcinoma	50%	120	17	29–71%
	9	G12D	Adenocarcinoma	70%	100	0	No signal
FFPE core tumor biopsies	10	G12C	Squamous cell carcinoma	40%	640	3	Outside quantifiable range
	11	G12C	Adenocarcinoma	65%	330	68	7–93%
	12	G12C	Adenocarcinoma	30%	200	20	25–75%

^aTumor content as specified by the supplier, based on hematoxylin and eosin (H&E) staining. ^bValues are based on the number fmol KRAS^G12C protein detected per 100 μg total protein, as shown in the previous column in this table, and the calculation of the high and low limit of engagement as outlined in the text. Engagement values outside of the quantifiable limits may still be assigned as being above or below the quantifiable limits, as discussed in the text. ^cFor samples with less than 100 µg total protein recovered, the value shown represents the amount of KRAS^G12C detected in the entirety of the sample.